We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Dr
for IF to state that tells me the studies are essentially complete now - imho
good to see FF+ other constituents explicitly mentioned
He's addressing the stock management post Jam day, he has options.
IF is a bean counter so he shall have a bias to keep the company balance sheet under very strict control - anyone else notice that the drop in income was within a few K of the fall in R&D spend.
Small rise in FF+ income reflects, imho, the carp social media effort by PXS.
Seeing the bad times at SiS reminds me of this video
https://youtu.be/GGsSBv1Cq90
W-please-cut-the-crust-off-my-jam-sandwiches-$
It’s good news that the jam is still on-track. The last 3 studies will complete within the next 13 weeks.
Reading through the results it does seem to me that the DSM agreement was quite restrictive on what pxs could or couldn’t do . I also think DSM had the lions share of the income so maybe only 10% came our way , why else would DSM hold €1m of inventory !
With €1m of stock you would hope that would be enough for several £m income from By health orders, so maybe when money starts rolling in it would pay for more production runs , but I suppose stock levels would have to be kept high in case of large and unexpected orders coming in , I’m no expert just my view .
Yes it is, but it's also an indication of the expenditure needed for repeat productions. Anticipating a big rise in orders, it could be that there would need to be a multi million inventory, which would be great news as long as the funding model is clear to us. BH haven't invested what they have for nothing IMHO
I think it depends how much stock DSM can shift in the last few months of the year ,whatever is left pxs could buy , so its a bit a bit of an unknown at this stage .
As I always do, let the blowhards have first go, I take some time to read in full what's in the reams of small print.
The business model of Provexis is on the verge of a step change. From the semi passive role of maintaining the IP, the full commercial aspects of procuring, stocking, and selling worldwide is under total control. A big challenge, but with the distinct benefit of being focussed entirely on Fruitflow, rather than being a small part of a colossal product range. As pointed out in June, there is a much higher margin accruing to the company going forwards, and any prospective customer has the advantage of dealing with the very highest level of technical knowledge.
IMHO we need better clarity on financing needs, dependant on the method decided to cover this, then, of course, we need to see ByHealth start to launch products to get the payback from their massive investment.
Watching from afar, hid behind the settee, seriously did anyone expect anything else today, waiting on China.Fullstop.
Another year ,another loss,not all bad though, no reduction in salary for dumb and dumber . Nice to see some karma for moony.
Blimey, I didn't realise that SiS had turned into a crock as well!
Even the believers haven't bothered to comment today. Says it all really!
Pxs website updated , at least Our main holders haven’t sold any , https://www.provexis.com/shareholder-information/major-shareholders/
Look on the positive side;At least we still haven't got Moon in charge;doing well again I see @SIS
Two sells so far, guessing that's CB and Nazir out...
It just shows you ,totally agree with the last statement.
Another year ,,what's happened about the blue cap
i ,believed the first half of 2022 we would've got feedback on the last three
A new worry is having to make a decision about buying remaining stock and how to finance it. It's just an endless saga and the company simply cannot make a profit after all these years.
Another empty jam jar. 15 years in this, and the reports always read the same... "Next year Rodders". Another cut and paste from prior year except where they need to provide more info for going concern purposes (or, in other words: please give us more money)
0.70 to buy?
We will see ,i hope you are right
Wait and see. Lots said that before last year's AGM and look what happened. Be happy
Nothing to report ,that's why leave it to the last day ,sp dropping again
Isn't that what most folks have been hoping for?
As I've soliloquied in the past, looks like FF is outgrowing us.
W$
Yes wellsite, its been popping up quite a lot in the internet but its good that it came directly from the By-Health website as we don't get a lot of good info from them.
"The discovery of this new mechanism further unveils the mystery of Qingluoxin" (fruitflow), "and provides more new ideas for its functional transformation and product landing. With the deepening of scientific research, it is expected to bring more health products with scientific and technological content to the public in the future"
May be taking longer than we first thought but the end result should be good.
Nice one gix
being cut and pasted
https://www-pharmnews-com.translate.goog/news/articleView.html?idxno=210755&_x_tr_sl=zh-CN&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
https://cj-sina-com-cn.translate.goog/articles/view/1820447737/6c81d3f9019016i7i?_x_tr_sl=zh-CN&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
W$
I don’t expect anything new in the results,we know revenue and unless By health have completed their 3 remaining studies I think the blue hat will be “progressing well”as usual , as someone has already pointed out revenue from the DSM transfer won’t become clear until after year end 23 . I hope there is some clarity on the huge ramp up in production needed and how it will be payed for .